Class B (4) of Grade 2014, Department of Clinical Medicine, Chongqing Medical University, Chongqing 400016, P.R. China.
Institute of Biomedical Engineering, Second Military Medical University, Shanghai 200433, P.R. China.
Mol Med Rep. 2019 Apr;19(4):2687-2697. doi: 10.3892/mmr.2019.9933. Epub 2019 Feb 5.
Engineered conduction tissues (ECTs) are cardiac conduction tissues fabricated in vitro to allow for more precisely targeted in vivo transplantation therapy. The transplantation of ECTs may be ideal for the treatment of atrioventricular conduction block and could have a significant impact on the future application of biological pacemakers. However, there is little published information regarding the conduction function of ECTs in vivo. In the present study, ECTs were constructed by seeding cardiac progenitor cells (CPCs) into a collagen sponge and were then transplanted into animal hearts to determine whether they could act as an atrioventricular conduction pathway. The results demonstrated that the transplanted ECTs were adequately vascularized at the early stage of transplantation and could survive in the atrioventricular junction area of rats. A large number of myocardial tissue (≥29% of the new muscle fiber tissue formation area in the implanted ECTs) were observed by Masson's trichrome staining at 60 days post-transplantation. Positive staining for connexin-40, connexin-43, HCN2 and cTnT was exhibited during the period of 20 to 90 days post-transplantation. This result suggested that the transplanted ECTs formed gap junctions with the allogeneic myocardium and developed into cardiac conduction tissues with certain myocardial components. Electrocardiography (ECG) confirmed that there was a clear pre-excitation syndrome in the rats transplanted with ECTs during the period of 20 to 90 days post-transplantation. The recovery rate in the rats implanted with ECTs was 61.54% within 1 h following atrioventricular block, and the heart rhythm following recovery was close to normal. By contrast, the recovery rate was only 4.17% in the rats implanted with blank collagen sponges (BCSs), and none of the sham rats exhibited atrioventricular block recovery. In conclusion, ECTs can survive and mechanically integrate with the allogeneic myocardium following transplantation into rat hearts. An atrioventricular accessory pathway similar to Kent bundles could be established between the atria and ventricles of rats following implantation. It is suggested that ECTs may be a potential substitution therapy for atrioventricular conduction block.
工程化传导组织 (ECT) 是在体外构建的心脏传导组织,可实现更精确的体内移植治疗。ECT 的移植可能是治疗房室传导阻滞的理想选择,并可能对生物起搏器的未来应用产生重大影响。然而,关于体内 ECT 的传导功能的文献报道很少。在本研究中,将心脏祖细胞 (CPC) 接种到胶原海绵中构建 ECT,然后将其移植到动物心脏中,以确定它们是否可以作为房室传导途径。结果表明,移植的 ECT 在移植的早期阶段得到充分的血管化,并能在大鼠房室交界处存活。Masson 三色染色显示,移植后 60 天,大量心肌组织(移植 ECT 中新肌纤维组织形成区的≥29%)。移植后 20 至 90 天期间,连接蛋白-40、连接蛋白-43、HCN2 和 cTnT 呈阳性染色。这一结果表明,移植的 ECT 与同种异体心肌形成缝隙连接,并发育成具有一定心肌成分的心脏传导组织。心电图 (ECG) 证实,移植 ECT 的大鼠在移植后 20 至 90 天期间出现明显的预激综合征。ECT 植入大鼠在房室传导阻滞后 1 小时内的恢复率为 61.54%,恢复后的心律接近正常。相比之下,植入空白胶原海绵 (BCS) 的大鼠的恢复率仅为 4.17%,且无假手术大鼠出现房室传导阻滞恢复。总之,ECT 移植到大鼠心脏后可存活并与同种异体心肌机械整合。在植入后,大鼠的心房和心室之间可能会建立类似于 Kent 束的房室附加通路。这表明 ECT 可能是治疗房室传导阻滞的一种潜在替代治疗方法。